TGFB1 and idiopathic pulmonary fibrosis: Reviewing potential candidate pathways that might offer novel therapeutic targets to treat IPF, Antoniou KM reported antibodies to TGFβ1 significantly reduced the cytokine experimental lung and kidney fibrosis and a receptor antagonist to this cytokine decreased accumulation of lung collagen induced by bleomycin [15].